Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and...
We haven't written up this one. The Hill has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com
- Merck, Moderna Melanoma Vaccine Study Succeeds bloomberg.com
- Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial cbc.ca
- Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine endpoints.news
- Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial qz.com
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial cnbc.com
- Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning nytimes.com
- Moderna share price doubles on melanoma vaccine trial success ft.com
